Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $80
JMP Securities Reiterates Market Outperform on Jasper Therapeutics, Maintains $70 Price Target
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $55 to $90
Jasper Therapeutics Analyst Ratings
Buy Rating Affirmed for Jasper Therapeutics Amidst Promising Briquilimab Clinical Data and Market Potential
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
Jasper Therapeutics Analyst Ratings
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Briquilimab Prospects and Strategic Development
BTIG Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $90
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
JMP Securities Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $70
Jasper Therapeutics Price Target Maintained With a $65.00/Share by Evercore ISI Group
Jasper Therapeutics Analyst Ratings
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Maintains $65 Price Target